<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01572818</url>
  </required_header>
  <id_info>
    <org_study_id>2008-A00636-49</org_study_id>
    <secondary_id>PHRC/07-05</secondary_id>
    <secondary_id>CIC0203/070</secondary_id>
    <nct_id>NCT01572818</nct_id>
  </id_info>
  <brief_title>Effects of Phlebotomy on Insulin Sensitivity in Insulin Resistance-associated Hepatic Iron Overload Patients</brief_title>
  <acronym>SAINPOS</acronym>
  <official_title>Effects of Phlebotomy on Insulin Sensitivity in Insulin Resistance-associated Hepatic Iron Overload Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy of phlebotomy on insulin sensitivity as&#xD;
      evaluated by euglycemic-hyperinsulinic clamp in insulin resistance-associated hepatic iron&#xD;
      overload patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to evaluate in patients with HSD effects of treatment&#xD;
      with phlebotomy rules with lifestyle and dietary rules versus lifestyle modifications alone&#xD;
      on peripheral insulin resistance (assessed by hyperinsulinemic clamp).&#xD;
&#xD;
      Secondary objectives are:&#xD;
&#xD;
        -  to study in all patients with HSD the relationship between the amount of iron&#xD;
           intrahepatic and degree of peripheral insulin resistance and liver before therapeutic&#xD;
           intervention.&#xD;
&#xD;
        -  to study and compare the effects of phlebotomy treatment versus no treatment on:&#xD;
&#xD;
             -  Plasma levels of adipocytokines,&#xD;
&#xD;
             -  Plasma concentrations of inflammatory markers and markers of insulin resistance,&#xD;
&#xD;
             -  The serum ferritin,&#xD;
&#xD;
             -  The post-hepatic clearance of insulin,&#xD;
&#xD;
             -  The surface of the abdominal visceral fat and subcutaneous abdominal.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose Infusion Rate by euglycemic-hyperinsulinic clamp</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>hepatic parameters</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammation markers</measure>
    <time_frame>6 months</time_frame>
    <description>IL-6, TNF alpha, CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipokins markers</measure>
    <time_frame>6 months</time_frame>
    <description>adiponectin, PAI1, leptin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SHBG</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic iron overload (MRI)</measure>
    <time_frame>6 months</time_frame>
    <description>transaminase (ALT, AST), gamma GT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal and sub-cutaneous fat surface (MRI)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>iron parameters</measure>
    <time_frame>at 6 months</time_frame>
    <description>serum iron, ferritin, saturation of transferrin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid profile</measure>
    <time_frame>at 6 months</time_frame>
    <description>HDL-c, LDL-c, triglycerides</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Iron Overload</condition>
  <arm_group>
    <arm_group_label>Phlebotomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>phlebotomy associated with dietary and lifestyle counseling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lifestyle counseling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dietary and lifestyle counseling</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>phlebotomy</intervention_name>
    <description>7 ml/kg without exceeding 500 mL</description>
    <arm_group_label>Phlebotomy</arm_group_label>
    <other_name>Non applicable.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>dietary and lifestyle counseling</intervention_name>
    <description>dietary and lifestyle counseling</description>
    <arm_group_label>Lifestyle counseling</arm_group_label>
    <arm_group_label>Phlebotomy</arm_group_label>
    <other_name>Non applicable.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 70 years&#xD;
&#xD;
          -  Ferritin between 450 and 1000 µg/L&#xD;
&#xD;
          -  Hepatic iron overload proved by MRI (CHF &gt;36 µmol/g)&#xD;
&#xD;
          -  Body mass index &gt; 25 kg/m²&#xD;
&#xD;
          -  Fasting glycemia &lt;1,26 g/L&#xD;
&#xD;
          -  HbA1c &lt; 6,5%&#xD;
&#xD;
          -  Signed written and informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other causes of hyperferritinemia:&#xD;
&#xD;
               -  Inflammatory syndrome (CRP &gt;10 mg/L) or inflammatory, immune or malignant&#xD;
                  diseases&#xD;
&#xD;
               -  Hyperferritinemia-cataract syndrome (familial cataract or personal history of&#xD;
                  cataract before 50 years old)&#xD;
&#xD;
               -  Low ceruloplasmin level&#xD;
&#xD;
               -  Porphyria (cutaneous signs)&#xD;
&#xD;
               -  Haemochromatosis established by the genotype (C282Y homozygous or C282Y/H63D&#xD;
                  coumpound heterozygous genotypes)&#xD;
&#xD;
          -  Contraindication of phlebotomy&#xD;
&#xD;
               -  Haemoglobin &lt;13,5 g/dL (threshold established by the Etablissement Français du&#xD;
                  Sang)&#xD;
&#xD;
               -  Heart failure or coronary heart diseases&#xD;
&#xD;
               -  Hepatic failure, renal (GFR &lt;50mL/min) or respiratory insufficiency (chronic&#xD;
                  dyspnea)&#xD;
&#xD;
               -  Poor venous system&#xD;
&#xD;
          -  Viral, immune, genetic, vascular, malignant or toxic chronic hepatic disease&#xD;
&#xD;
          -  Alcohol consumption more than 21 doses per week during 5 years or more&#xD;
&#xD;
          -  Type 1 or type 2 diabetes&#xD;
&#xD;
          -  Oral anti-diabetic, corticoids or immune suppressor drugs&#xD;
&#xD;
          -  Hepatic severe disease&#xD;
&#xD;
          -  Claustrophobia, having a pace-maker or intracerebral clips&#xD;
&#xD;
          -  Subjects deprived of their liberty by judicial or administrative decision, subjects&#xD;
             that are not affiliated to social security or topics exclusion period of a previous&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice BONNET, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Bellissant, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>RennesUniversity Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Nantes</city>
        <zip>F-44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Rennes</city>
        <zip>F-35203</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>May 17, 2011</study_first_submitted>
  <study_first_submitted_qc>April 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2012</study_first_posted>
  <last_update_submitted>June 14, 2016</last_update_submitted>
  <last_update_submitted_qc>June 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phlebotomy</keyword>
  <keyword>Insulin Resistance</keyword>
  <keyword>Iron Overload</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Iron Overload</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

